Mark Samuels, managing director of the UK's National Institute for Health Research Office for Clinical Research Infrastructure, told the paper: "We are exploring the real possibility of curing HIV. This is a huge challenge and it's still early days but the progress has been remarkable."
HIV targets the immune system, attaching itself to the DNA of T-cells, where the disease can both hide out and reproduce.
Current antiretroviral therapies (Art) target that process but cannot spot dormant infected T-cells.
The new therapy works firstly by recognising and removing the HIV-infected cells. In the next stage, a new drug called Vorinostat turns the dormant T-cells active so that they can be spotted and then targeted by the immune system.
Around 37 million are living with HIV worldwide, many of them in Sub-Saharan Africa.